Norway· NO-ID_AA7DFCC6-3738-4B68-BCED-BC7BD01A618F
Gemcitabine Accord
A gemcitabine product containing gemcitabine, registered in Norway by Accord Healthcare B.V.. The same ATC class is registered in 17 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Gemcitabine is registered in 17 of 19 countries.
Countries holding a registration under ATC L01BC05 (gemcitabine), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 10 of them publish a price we can compare per daily dose
Gemcitabine · ATC L01BC05
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of gemcitabine costs, country by country.
Normalised to the WHO defined daily dose (0.2 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Gemcitabine · price per daily dose (0.2 g)
USD · FX 28 Sept 2026
- CH Switzerland$27.60
The record
At a glance
FEST (Norway)- Active substance
- Gemcitabine
- Manufacturer
- Accord Healthcare B.V.
- Country
- Norway (NO)
- ATC code
- L01BC05
- ATC class
- Gemcitabine
- Defined daily dose
- 0.2 g, P
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 9
4 priced- gtin5055565701904
- no_merkevare_idID_AA7DFCC6-3738-4B68-BCED-BC7BD01A618F
- no_varenummer4168811 x 15NOK 2657.3
- no_varenummer0877401 x 2NOK 387.7
- no_varenummer0873901 x 20NOK 3531
- no_varenummer1293451 x 10NOK 1783.6
- gtin5055565701898
- gtin5055565701874
- gtin5055565701881
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
370 interactions on record for gemcitabine.
Graded by severity as the source publishes them — 33 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Gemcitabine · interactions on record
370 records
- 33 severe
- 114 moderate
- 19 minor
- 204 info
Most severe, free to view
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- CladribineL01BB04severe
- PexidartinibL01EX15severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Gemcitabine in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumGemcitabine Accord Healthcare 100 mg/mlAccord Healthcare
- CzechiaGEMCITABINE ACCORDACCORD HEALTHCARE POLSKA Sp. z o.o., Varšava
- IrelandGemcitabine 100 mg/ml Concentrate for Solution for InfusionAccord Healthcare Ireland Ltd.
- PolandGemcitabinum AccordAccord Healthcare Polska Sp. z o.o.
- SwedenGemcitabine Accord 100 mg/ml Koncentrat till infusionsvätska, lösningAccord Healthcare B.V.
- FinlandGemcitabine AccordAccord Healthcare B.V.
- SwitzerlandGemcitabin Accord 1500 mg/15 ml, Konzentrat zur Herstellung einer InfusionslösungAccord Healthcare AG
- United KingdomGemcitabine 1.2g/120ml infusion bagsSun Pharma UK Ltd
Authorised across Europe · EMA
The same active substance is authorised in 29 EEA countries. Names it is sold under:
- Austria · Gemcitabin Accord, Gemcitabin Ebewe
- Belgium · Gemcitabin Sandoz, Gemcitabin Sun
- Bulgaria · Гемсол, Гемцитабин Акорд
- Cyprus · Gemcitabine Accord, Gemnil
- Czechia · Gemcitabin Ebewe, Gemcitabin Sun
- Germany · Bendacitabin, Gemci-Cell
- Denmark · Gemcitabin "sandoz", Gemcitabin Accord
- Estonia · Gemcitabine Accord, Gemcitabine Kabi
- Spain · Gemcitabina Accord, Gemcitabina Aurovitas Spain
- Finland · Gemcitabin Accord, Gemcitabin Sandoz
- France · Gemcitabine Accord, Gemcitabine Arrow
- United Kingdom (Northern Ireland) · Gemcitabine Accord Healthcare, Gemcitabine Ennogen Ip
- Greece · Demozar, Gemcipen
- Croatia · Gemcitabin Accord, Gemcitabin Sandoz
- Hungary · Gemcitabin Kabi, Gemcitabine Accord
- Ireland · Gemcitabine, Gemcitabine Accord Healthcare
- Iceland · Gemcitabin Wh, Gemkabi
- Italy · Gemcitabina Accord, Gemcitabina Aurobindo Pharma Italia
- Lithuania · Gemcitabine Accord, Gemcitabine Kabi
- Luxembourg · Gemcitabine Eg, Gemcitabine Eugia
- Latvia · Gemcitabine Accord, Gemcitabine Kabi
- Malta · Gemcitabine Pfizer Hellas, Gemnil
- Netherlands · Gemcitabine Accord, Gemcitabine Fresenius Kabi
- Poland · Gemcitabine Kabi, Gemcitabinum Accord
- Portugal · Gemcit, Gemcitabina Accord
- Romania · Gemcitabină Accord, Gemcitabina Kabi
- Sweden · Gemcitabin Sandoz, Gemcitabin Sun
- Slovenia · Gemcitabin Accord, Gemcitabin Kabi
- Slovakia · Gemcitabín Sun, Gemcitabine Accord
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d3eb2736-2222-4f0b-8e98-c6390215fa8b GET /v1/drugs/d3eb2736-2222-4f0b-8e98-c6390215fa8b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Konsentrat til infusjonsvæske, oppløsning",
"source": "fest",
"status": "A",
"atc_name": "Gemcitabin",
"merkevare_id": "ID_AA7DFCC6-3738-4B68-BCED-BC7BD01A618F",
"name_form_strength": "Gemcitabine Accord kons til inf oppl 100 mg/ml",
"prescription_group": "C"
}See everything about gemcitabine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.